Publications by authors named "D Triulzi"
Background: Clinical guidelines have concluded that there are insufficient data to provide recommendations for the hemoglobin threshold for the use of red cell transfusion in patients with acute myocardial infarction (MI) and anemia. After the recent publication of the Myocardial Infarction and Transfusion (MINT) trial, we performed an individual patient-level data meta-analysis to evaluate the effect of restrictive versus liberal blood transfusion strategies.
Methods: We conducted searches in major databases.
COVID-19 convalescent plasma (CCP) was one of the first therapies to receive emergency use authorization for management of COVID-19. We assessed the effectiveness of CCP in a propensity-matched analysis, and whether the presence of antibodies in the recipient at the time of treatment or the titer of antibodies in the administered CCP influenced clinical effectiveness. In an inpatient population within a single large health system, a total of 290 CCP patients were matched to 290 controls.
View Article and Find Full Text PDFArticle Synopsis
- Scientists studied people with low blood platelets who might bleed more easily, even when they got extra platelets.
- They found that 46% of the 330 participants experienced significant bleeding, with similar results for those taking medicine and those who didn’t.
- The research showed that having very low platelets and low red blood cells increased the risk of bleeding, suggesting that doctors might need to help raise red blood cell levels to prevent this.
Background: Granulocyte transfusions for patients with prolonged neutropenia and severe infections has been a controversial practice. Previous studies suggest a benefit of high-dose granulocyte transfusions (≥0.6 × 10/kg), although, until recently, the consistent production of high-dose units has been challenging.
View Article and Find Full Text PDFBackground: Tranexamic acid (TXA) is an antifibrinolytic agent that reduces bleeding in a multitude of clinical settings from postpartum hemorrhage to trauma. TXA may have clinical effects unrelated to bleeding; plasminogen, the target of TXA, alters immune responses, and TXA appears to decrease the risk of infection in patients undergoing cardiac surgery, as well as joint arthroplasty.
Objectives: To address whether TXA alters rates of infection and inflammatory outcomes in patients with hematologic malignancies.